Anbison Pharmaceutical

Ethypharm, a France-based pharmaceutical company, has announced that its Chinese subsidiary, Shanghai Ethypharmaceuticals Ltd, has finalized an acquisition of a mesalazine suppository product from Jiangsu Anbison Pharmaceutical. This product is indicated for the treatment of inflammatory bowel diseases (IBD), including ulcerative colitis and Crohn’s disease. The financial details and other…